APO-MOXIFLOXACIN 400 MG — DIN 02404923
MOXIFLOXACIN (MOXIFLOXACIN HYDROCHLORIDE) : 400 MG · APOTEX INC · TABLET · wholesale supply in Canada
Health Canada status: DORMANT
What is APO-MOXIFLOXACIN?
APO-MOXIFLOXACIN 400 MG contains MOXIFLOXACIN (MOXIFLOXACIN HYDROCHLORIDE) : 400 MG. It is listed in the Health Canada Drug Product Database under DIN 02404923, held by APOTEX INC, supplied as TABLET for ORAL administration. Health Canada currently lists it as dormant, status dated 08-Apr-2026. Nexara Health is a licensed Canadian wholesale distributor (DEL 3-002896-A). This DIN is not currently being marketed in Canada, so it is sourced to order where a compliant route exists rather than held in stock.
What is APO-MOXIFLOXACIN used for?
APO-MOXIFLOXACIN (moxifloxacin hydrochloride) is indicated for the treatment of adults (≥18 years of age) with bacterial infections caused by susceptible strains of designated microorganisms, including acute bacterial sinusitis, acute bacterial exacerbation of chronic bronchitis, community-acquired pneumonia (mild to moderate, and in hospitalized patients), complicated intra-abdominal infections, and complicated skin and skin structure infections in hospitalized patients.
Authorized indication as written in the Health Canada product monograph. For healthcare professionals and licensed purchasers; this is not medical advice.
How much does Moxifloxacin cost around the world?
Moxifloxacin is listed on 12 of the national price registers Nexara ingests. Each country publishes on a different basis, so those figures are not comparable with one another — or with a Canadian wholesale price.
What a market publishes matters more than the number it publishes. Austria publishes a KVP (Kassenverkaufspreis); Bahrain publishes a retail (max); Czechia publishes a max producer price (ex-factory). Comparing an ex-factory ceiling against a pharmacy public price tells you nothing about either, and comparing either against a Canadian landed cost tells you less.
| Market | Price basis published there | Brands | Packs listed | Range |
|---|---|---|---|---|
| South Africa | single exit price | 20 | 27 | ZAR███.██ |
| United States | acquisition | 2 | 21 | USD███.██ |
| Bahrain | retail (max) | 11 | 17 | BHD███.██ |
| Austria | KVP (Kassenverkaufspreis) | 6 | 15 | EUR███.██ |
| Sweden | AIP (pharmacy purchase price) | 6 | 14 | SEK███.██ |
| Greece | producer price (ex-factory) | 13 | 13 | EUR███.██ |
| Romania | max producer price | 9 | 13 | RON███.██ |
| Luxembourg | reimbursement | 8 | 8 | EUR███.██ |
| Hungary | producer price (ex-factory) | 2 | 7 | HUF███.██ |
| Iceland | max wholesale | 3 | 3 | ISK███.██ |
| United Kingdom | hospital | 2 | 2 | GBP███.██ |
| Czechia | max producer price (ex-factory) | 1 | 1 | CZK███.██ |
141 pack listings across 83 brand entries and 11 price bases, refreshed 05 Sep 2026. Ranges span every Moxifloxacin pack in that market, so a high figure is usually a larger pack rather than the same product.
Canada publishes no comparable public list price. For a delivered Canadian price on a licensed account, verify your licence — it takes about a minute.
Is there a generic Moxifloxacin in Canada, and who makes it?
Every market authorization holder with a Canadian DIN for this molecule, and how many of their listings Health Canada currently shows as marketed.
21 holders have a Canadian DIN containing Moxifloxacin, across 25 DINs, of which 8 are currently marketed. Marketed count is the number that matters: an approval that is not marketed cannot be bought.
| Market authorization holder | DINs | Marketed | Brand names | Position |
|---|---|---|---|---|
| JAMP PHARMA CORPORATION | 2 | 1 | JAMP-MOXIFLOXACIN, JAMP-MOXIFLOXACIN TABLETS | Sourceable in Canada |
| AURO PHARMA INC | 1 | 1 | AURO-MOXIFLOXACIN | Sourceable in Canada |
| FRESENIUS KABI CANADA LTD | 1 | 1 | MOXIFLOXACIN INJECTION | Sourceable in Canada |
| MANTRA PHARMA INC | 1 | 1 | M-MOXIFLOXACIN | Sourceable in Canada |
| PRO DOC LIMITEE | 1 | 1 | MOXIFLOXACIN | Sourceable in Canada |
| SANDOZ CANADA INCORPORATED | 1 | 1 | SANDOZ MOXIFLOXACIN | Sourceable in Canada |
| SANIS HEALTH INC | 1 | 1 | MOXIFLOXACIN | Sourceable in Canada |
| TEVA CANADA LIMITED | 1 | 1 | TEVA-MOXIFLOXACIN | Sourceable in Canada |
| APOTEX INC | 2 | 0 | APO-MOXIFLOXACIN, APO-MOXIFLOXACIN HYDROCHLORIDE | No marketed DIN |
| BAYER INC | 2 | 0 | AVELOX, AVELOX I.V. | No marketed DIN |
| MARCAN PHARMACEUTICALS INC | 2 | 0 | IPG-MOXIFLOXACIN, MAR-MOXIFLOXACIN | No marketed DIN |
| TORRENT PHARMACEUTICALS LIMITED | 1 | 0 | TORRENT-MOXIFLOXACIN | No marketed DIN |
Health Canada’s Drug Product Database does not flag which listing is the originator and which are subsequent-entry products, so Nexara does not label them here. Interchangeability is determined provincially, not federally — confirm for your province before a formulary switch. Nexara can confirm which of these is actually obtainable, and on what lead time, per order.
How is it supplied and stored?
Pack configuration, storage class and the handling constraints that drive cold-chain planning. One DIN can cover more than one pack size, and the pack — not the DIN — is what gets priced, shipped and invoiced.
| Strength on the label | 400 MG |
|---|---|
| Dosage form | TABLET |
| Route | ORAL |
| Pack configuration (monograph) | null |
| Storage | null |
Before an order line is unambiguous Nexara needs the strength, the pack size and the presentation.
Substance and classification
| Active substance | Moxifloxacin |
|---|---|
| ATC code | J01MA14 |
| AHFS class | 08:12.18 |
| Biosimilar biologic | No |
Health Canada record and identifiers
The regulatory facts straight from the Drug Product Database, plus every identifier form Nexara accepts on a purchase order. A DIN written without its leading zeros is the commonest reason an order line fails to match.
| DIN (8-digit, as used in ordering) | 02404923 |
|---|---|
| DIN (unpadded, as printed on some documents) | 2404923 |
| Brand name | APO-MOXIFLOXACIN |
| Generic / active ingredient | MOXIFLOXACIN (MOXIFLOXACIN HYDROCHLORIDE) : 400 MG |
| Market authorization holder | APOTEX INC |
| Health Canada schedule | Prescription |
| ATC code | J01MA14 |
| ATC anatomical main group | J — Anti-infectives for systemic use |
| ATC therapeutic subgroup | J01MA |
| Current status | DORMANT |
| Status date | 08-Apr-2026 |
| Original market date | 2016-01-11 00:00:00 |
| Status source | Live Health Canada DPD sync |
Verify on the primary sources
Is Moxifloxacin in shortage in Canada?
A Canadian shortage report is on file for a product containing this molecule: Active — reported by SANIS HEALTH INC, last seen 09 Sep 2026. A shortage on one presentation does not always affect every DIN of the molecule — the alternatives below list what else is marketed in Canada. Nexara can confirm current availability and identify substitutions or import options where permitted.
What can be used instead?
Alternatives on every axis a buyer actually considers — the same molecule in another presentation, the same class, an adjacent class, or a fixed-dose combination. Every row is led by the marketed DIN count, because that is what can be bought this week.
1 · Same molecule, other Canadian presentations
8 of 25 Canadian DINs for this molecule are currently marketed. Marketed products are listed first.
| Product | Strength | Form | Holder | Health Canada status | DIN |
|---|---|---|---|---|---|
| AURO-MOXIFLOXACIN | 400 MG | TABLET | AURO PHARMA INC | MARKETED | 02432242 |
| JAMP-MOXIFLOXACIN | 400 MG | TABLET | JAMP PHARMA CORPORATION | MARKETED | 02443929 |
| M-MOXIFLOXACIN | 400 MG | TABLET | MANTRA PHARMA INC | MARKETED | 02472791 |
| MOXIFLOXACIN | 400 MG | TABLET | PRO DOC LIMITEE | MARKETED | 02462974 |
| MOXIFLOXACIN | 400 MG | TABLET | SANIS HEALTH INC | MARKETED | 02520710 |
| MOXIFLOXACIN INJECTION | 400 MG / 250 ML | SOLUTION | FRESENIUS KABI CANADA LTD | MARKETED | 02433087 |
| SANDOZ MOXIFLOXACIN | 400 MG | TABLET | SANDOZ CANADA INCORPORATED | MARKETED | 02383381 |
| TEVA-MOXIFLOXACIN | 400 MG | TABLET | TEVA CANADA LIMITED | MARKETED | 02375702 |
| AG-MOXIFLOXACIN | 400 MG | TABLET | ANGITA PHARMA INC. | DORMANT | 02478137 |
| APO-MOXIFLOXACIN HYDROCHLORIDE | 400 MG | TABLET | APOTEX INC | APPROVED | 02517108 |
2 · Same class — other molecules in ATC J01MA
| Molecule | Canadian brands | DINs | Marketed | Sourceable |
|---|---|---|---|---|
| Ciprofloxacin | ACT CIPROFLOXACIN · AG-CIPROFLOXACIN · APO-CIPROFLOX · AURO-CIPROFLOXACIN · +50 more | 139 | 29 | Yes |
| Levofloxacin | ACT LEVOFLOXACIN · APO-LEVOFLOXACIN · AURO-LEVOFLOXACIN · AVA-LEVOFLOXACIN · +19 more | 54 | 16 | Yes |
| Moxifloxacin | AG-MOXIFLOXACIN · APO-MOXIFLOXACIN · APO-MOXIFLOXACIN HYDROCHLORIDE · AURO-MOXIFLOXACIN · +20 more | 25 | 8 | Yes |
| Delafloxacin | BAXDELA | 2 | 2 | Yes |
| Norfloxacin | AVA-NORFLOXACIN · CO NORFLOXACIN · NORFLOXACIN · NORFLOXACINE-400 · +5 more | 12 | 1 | Yes |
| Ofloxacin | FLOXIN I.V. LIQ 20MG/ML · FLOXIN TABLETS 200MG · FLOXIN TABLETS 300MG · FLOXIN TABLETS 400MG · +2 more | 10 | 0 | Not in Canada |
| Gatifloxacin | NOVO-GATIFLOXACIN · TEQUIN · TEQUIN IV | 5 | 0 | Not in Canada |
| Trovafloxacin | TROVAN I.V. · TROVAN TABLETS 100MG · TROVAN TABLETS 200MG | 3 | 0 | Not in Canada |
| Grepafloxacin | RAXAR | 1 | 0 | Not in Canada |
| Gemifloxacin | FACTIVE | 1 | 0 | Not in Canada |
A molecule with zero marketed DINs cannot be sourced domestically, however many approvals it holds — if one of these sits on a formulary or in an older protocol, that is the line to check.
3 · Adjacent classes in ATC J01M
| ATC subgroup | Molecules | DINs | Marketed |
|---|---|---|---|
| J01MB | Nalidixic Acid | 1 | 0 |
Not clinical advice. These tables describe what can be supplied in Canada, not what should be prescribed. Substitution within or across classes is a prescriber and pharmacist decision, and interchangeability is determined provincially.
What else is APO-MOXIFLOXACIN called?
The same molecule, Moxifloxacin, is registered under other names elsewhere. Buyers and prescribers searching from outside Canada — or working from a foreign prescription or tender document — often know it by one of these:
| Name | Script | Registered in |
|---|---|---|
| Avalox | Latin | Bahrain, Iceland |
| Avelox | Latin | Iceland, Sweden |
| Moxifloxacin Krka | Latin | Sweden |
| Moxifloxacin Orion | Latin | Sweden |
| Avoxa | Latin | South Africa |
| DRL Moxifloxacin | Latin | South Africa |
| Litares | Latin | South Africa |
| MICROMOX | Latin | Bahrain |
| Moxibay Tablets | Latin | South Africa |
| Moxifloxacin Abacus Medicine | Latin | Sweden |
| MOXIVE | Latin | Bahrain |
| MUXAVA | Latin | Bahrain |
| Ran-Moxifloxacin | Latin | South Africa |
| XFLOX | Latin | Bahrain |
| AROX | Latin | Bahrain |
Names are taken from national medicine registers and published price lists. A product registered abroad is not authorized for sale in Canada unless it holds its own DIN; import is possible only through the routes Health Canada permits.
How can I get it?
This DIN is dormant — it holds a Health Canada authorization but is not currently being marketed in Canada, so it cannot simply be ordered from Canadian stock. Where a patient need exists, supply may be possible through exceptional importation or the Special Access Programme, subject to Health Canada's requirements and the prescriber's application. Nexara can advise on the route and on marketed alternatives.
Ordering questions
Who can buy this from Nexara?
Licensed entities only. Nexara holds Health Canada establishment licence DEL 3-002896-A and ships only to a licensed address. Patients and unlicensed buyers are routed to a partner pharmacy.
Is there a minimum order?
Yes, set per product line and per pack multiple rather than on the order total, so you are never asked to buy a part-pack. The minimum for this line is confirmed with your quote.
What is the lead time?
Confirmed per order at quotation, and it depends on current stock position and whether the product is in shortage.
Why is there no price on this page?
Nexara quotes a delivered Canadian price per order, against a verified licence. Foreign list prices are published on incompatible bases and are not a guide to what any buyer can obtain here, so this page shows which markets list the molecule and on what basis, and nothing more.
Can Nexara supply this for a clinical trial?
Yes — comparator and background-therapy supply, including sourcing from other markets where a Canadian pack will not satisfy the protocol. Clinical trial supply.